NCT03840512 - An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 12, 2018

Primary Completion Date

November 15, 2022

Study Completion Date

December 15, 2022

Conditions

Prevention aGVHD

Interventions

DRUG

CBD

"CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin."

Trial Locations (5)

2010

St Vincent's Hospital Sydney - The Kinghorn Cancer Centre, Sydney

49100

Davidof Cancer Center, Beilinson hospital, Rabin medical center, Petah Tikva

91120

Hadassah Medical Center - Bone Marrow Transplantation Department, Cancer Immunotherapy and Immunobiology Research Center, Jerusalem

3109601

Rambam Health Care - Bone Marrow Transplantation Unit, Haifa

Unknown

Tel-Aviv Sourasky Medical Center - Bone Marrow Transplantation Unit, Tel Aviv